Total 3-P MACE

There is 1 paper on total 3-P MACE in aging research: 1 trial in people. The newest story, Oct 26, 2026: “Evolocumab reduced total cardiovascular events in high-risk patients”.

Disease

1 paper studies it1 more mentions it1 finding

2 new papers in 30 daysSee all 2 papers on total 3-P MACE

  • Human trial1

Interventions

1

Evolocumab

downin humans1

1 study
  1. Evolocumab decreases total 3-P MACE in humans (first and subsequent events analyzed together with negative binomial regression) (27% fewer total events (IRR 0.73, 95% CI 0.63-0.86)).

    “total events by 27% (IRR 0.73, 95% CI 0.63-0.86; p<0.001)”

    Human trialfirst and subsequent events analyzed together with negative binomial regressionmedian of 4.6 yearsn = 12,257

    Evolocumab reduced total cardiovascular events in high-risk patients

    ESC Congress 2026 abstract

More on Evolocumab

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 1Nov 2026: 12 papers in 12 months
ESC Congress 2026 Abstract

Evolocumab reduced total cardiovascular events in high-risk patients

Evolocumab reduced the combined rate of coronary heart disease deaths, heart attacks and strokes caused by blocked blood flow by 27% versus placebo.Evolocumab reduced the combined rate of coronary heart disease deaths, heart attacks and strokes caused by blocked blood flow by 27% versus placebo.

Randomized trial · 12,257 peopleEvolocumab
JAMA Cardiology

Oral semaglutide reduced total major cardiovascular events

Nonfatal heart attacks and strokes plus cardiovascular deaths totaled 683 with oral semaglutide versus 791 with placebo over a median 49.5 months.Nonfatal heart attacks and strokes plus cardiovascular deaths totaled 683 with oral semaglutide versus 791 with placebo over a median 49.5 months.

Randomized trial · 9,650 peopleSemaglutide